Published in Emerg Infect Dis on August 01, 2002
Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis (2007) 3.73
Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. J Clin Microbiol (2005) 2.75
Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis (2005) 2.52
Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J Clin Microbiol (2006) 2.49
Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother (2005) 2.47
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis (2005) 1.70
Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. Antimicrob Agents Chemother (2008) 1.30
Isolation and genetic characterization of metallo-β-lactamase and carbapenamase producing strains of Acinetobacter baumannii from patients at Tehran hospitals. Iran J Microbiol (2011) 1.26
Endophthalmitis caused by Acinetobacter baumannii: report of two cases. J Clin Microbiol (2008) 1.07
The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci (2011) 1.02
Nosocomial infections in pediatric population and antibiotic resistance of the causative organisms in north of iran. Iran Red Crescent Med J (2014) 0.96
Application of a microsphere-based array for rapid identification of Acinetobacter spp. with distinct antimicrobial susceptibilities. J Clin Microbiol (2007) 0.95
Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One (2010) 0.95
Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J Clin Microbiol (2004) 0.92
Lytic myophage Abp53 encodes several proteins similar to those encoded by host Acinetobacter baumannii and phage phiKO2. Appl Environ Microbiol (2011) 0.90
Isolation and characterization of φkm18p, a novel lytic phage with therapeutic potential against extensively drug resistant Acinetobacter baumannii. PLoS One (2012) 0.90
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases (2014) 0.88
Molecular epidemiology of Acinetobacter baumannii in different hospitals in Tripoli, Lebanon using bla(OXA-51-like) sequence based typing. BMC Microbiol (2015) 0.84
Potential of bacteriophage ΦAB2 as an environmental biocontrol agent for the control of multidrug-resistant Acinetobacter baumannii. BMC Microbiol (2013) 0.82
The mode of inhibitor binding to peptidyl-tRNA hydrolase: binding studies and structure determination of unbound and bound peptidyl-tRNA hydrolase from Acinetobacter baumannii. PLoS One (2013) 0.82
Antimicrobial susceptibility patterns of the gram-negative bacteria isolated from septicemia in Children's Medical Center, Tehran, Iran. J Prev Med Hyg (2014) 0.81
Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients. Ann Clin Microbiol Antimicrob (2014) 0.80
Laboratory to Clinical Investigation of Carbapenem Resistant Acinetobacter baumannii Outbreak in a General Hospital. Jundishapur J Microbiol (2014) 0.80
Code blue: Acinetobacter baumannii, a nosocomial pathogen with a role in the oral cavity. Mol Oral Microbiol (2014) 0.80
Clinical characteristics and therapeutic outcomes of nosocomial super-infection in adult bacterial meningitis. BMC Infect Dis (2011) 0.79
Infections Caused by Acinetobacter baumannii in Recipients of Hematopoietic Stem Cell Transplantation. Front Oncol (2014) 0.79
Pharmacodynamics modeling to optimize dosage regimens of sulbactam. Antimicrob Agents Chemother (2013) 0.78
Severe pneumonia in the elderly: a multivariate analysis of risk factors. Int J Clin Exp Med (2015) 0.78
Admission surveillance cultures among patients admitted to intensive care unit. N Am J Med Sci (2012) 0.77
Endophthalmitis caused by Acinetobacter baumanni: a case series. Eye (Lond) (2013) 0.77
Acinetobacter baumannii producing OXA-23 detected in the Czech Republic. Springerplus (2013) 0.75
Persistence of antibiotic resistance plasmids in bacterial biofilms. Evol Appl (2017) 0.75
Tracing the emergence of multidrug-resistant Acinetobacter baumannii in a Taiwanese hospital by evaluating the presence of integron gene intI1. J Negat Results Biomed (2014) 0.75
Antimicrobial Resistance of Acinetobacter baumannii to Imipenem in Iran: A Systematic Review and Meta-Analysis. Open Microbiol J (2016) 0.75
Clinical response and outcome of pneumonia due to multi-drug resistant Acinetobacter baumannii in critically ill patients. Iran J Microbiol (2016) 0.75
Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii. Antimicrob Agents Chemother (2016) 0.75
Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. BMC Infect Dis (2016) 0.75
Impact of empirical antimicrobial therapy on the outcome of critically ill patients with Acinetobacter bacteremia. Ann Thorac Med (2015) 0.75
Bacteria killing nanotechnology Bio-Kil effectively reduces bacterial burden in intensive care units. Eur J Clin Microbiol Infect Dis (2013) 0.75
Assessing antibiotic therapy for Acinetobacter baumannii infections in an academic medical center. Eur J Clin Microbiol Infect Dis (2008) 0.75
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates. Antimicrob Agents Chemother (2017) 0.75
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
CDC definitions for nosocomial infections, 1988. Am J Infect Control (1988) 27.03
Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet (1994) 5.73
Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother (2001) 4.72
National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System. Am J Infect Control (1999) 4.30
Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis (1999) 3.77
Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol (2000) 3.23
Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J Clin Microbiol (2000) 3.21
Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother (1998) 2.94
Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 kDa outer membrane protein. J Antimicrob Chemother (1996) 2.60
Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis (1996) 2.37
Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am J Med Sci (1977) 2.28
Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol (1994) 2.01
Emergence of carbapenem-hydrolyzing enzymes in Acinetobacter baumannii clinical isolates. J Clin Microbiol (1999) 1.94
Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies. Antimicrob Agents Chemother (1997) 1.87
Current status of antimicrobial resistance in Taiwan. Emerg Infect Dis (2002) 1.55
Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J Clin Microbiol (1998) 1.52
Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1996) 1.50
Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother (1997) 1.39
Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis (2002) 1.19
Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb Drug Resist (2001) 1.09
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. J Antimicrob Chemother (2002) 1.05
Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain. Eur J Clin Microbiol Infect Dis (1998) 0.96
In vitro activities of ampicillin-sulbactam and amoxicillin-clavulanic acid against Acinetobacter baumannii. J Clin Microbiol (1998) 0.86
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas). J Antimicrob Chemother (2000) 0.84
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008) 5.34
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol (2013) 4.20
Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy. J Infect (2013) 3.45
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res (2011) 2.81
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res (2008) 2.60
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer (2006) 2.27
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. J Formos Med Assoc (2009) 2.15
Outcome correlation of smear-positivity for acid-fast bacilli at the fifth month of treatment in non-multidrug-resistant TB. Chest (2013) 2.09
Antimicrobial drug-resistant microbes associated with hospitalized community-acquired and healthcare-associated pneumonia: a multi-center study in Taiwan. J Formos Med Assoc (2012) 2.03
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.95
Ciprofloxacin-resistant Salmonella enterica Typhimurium and Choleraesuis from pigs to humans, Taiwan. Emerg Infect Dis (2004) 1.94
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents (2005) 1.94
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol (2008) 1.93
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med (2005) 1.88
Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother (2007) 1.84
Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res (2005) 1.84
Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan. Clin Infect Dis (2008) 1.79
High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother (2003) 1.75
Performance assessment of a nested-PCR assay (the RAPID BAP-MTB) and the BD ProbeTec ET system for detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol (2004) 1.67
Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol (2002) 1.63
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med (2008) 1.59
Novel characteristics of community-acquired methicillin-resistant Staphylococcus aureus strains belonging to multilocus sequence type 59 in Taiwan. Antimicrob Agents Chemother (2007) 1.56
Lower gastrointestinal tract tuberculosis: an important but neglected disease. Int J Colorectal Dis (2009) 1.55
Changes in B-type natriuretic peptide improve weaning outcome predicted by spontaneous breathing trial. Crit Care Med (2008) 1.55
Current status of antimicrobial resistance in Taiwan. Emerg Infect Dis (2002) 1.55
A rare constellation of empyema, lung abscess, and mediastinal abscess as a complication of endobronchial ultrasound-guided transbronchial needle aspiration. Eur J Cardiothorac Surg (2010) 1.54
Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci U S A (2011) 1.53
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations. Medicine (Baltimore) (2011) 1.52
Streptococcus suis infection. J Microbiol Immunol Infect (2005) 1.51
Mycobacterium tuberculosis in Taiwan. J Infect (2005) 1.46
groESL sequence determination, phylogenetic analysis, and species differentiation for viridans group streptococci. J Clin Microbiol (2002) 1.45
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer (2011) 1.43
Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care (2014) 1.43
Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever. Crit Care Med (2011) 1.41
Fas/Fas ligand pathway is involved in the resolution of type II pneumocyte hyperplasia after acute lung injury: evidence from a rat model. Crit Care Med (2002) 1.41
Non-human immunodeficiency virus Pneumocystis jiroveci pneumonia. Respirology (2013) 1.37
Structure and specific detection of staphylococcal cassette chromosome mec type VII. Biochem Biophys Res Commun (2008) 1.36
The LuxR family protein SpnR functions as a negative regulator of N-acylhomoserine lactone-dependent quorum sensing in Serratia marcescens. Mol Microbiol (2002) 1.36
Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res (2008) 1.33
Disseminated tuberculosis: a 10-year experience in a medical center. Medicine (Baltimore) (2007) 1.31
Performance assessment of the Capilia TB assay and the BD ProbeTec ET system for rapid culture confirmation of Mycobacterium tuberculosis. Diagn Microbiol Infect Dis (2007) 1.31
Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res (2006) 1.29
Brain abscess: clinical experience and analysis of prognostic factors. Surg Neurol (2005) 1.29
Diagnosis of tuberculosis by an enzyme-linked immunospot assay for interferon-gamma. Emerg Infect Dis (2007) 1.25
Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother (2011) 1.25
Factors influencing visibility and diagnostic yield of transbronchial biopsy using endobronchial ultrasound in peripheral pulmonary lesions. Respirology (2009) 1.25
Timing of tracheostomy as a determinant of weaning success in critically ill patients: a retrospective study. Crit Care (2004) 1.23
Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother (2003) 1.22
Preparation of enamides via palladium-catalyzed amidation of enol tosylates. Org Lett (2005) 1.22
Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc Natl Acad Sci U S A (2012) 1.22
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One (2011) 1.21
Arrival of Klebsiella pneumoniae carbapenemase (KPC)-2 in Taiwan. J Antimicrob Chemother (2011) 1.20
Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol (2011) 1.20
Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis (2002) 1.19
The erm(T) gene is flanked by IS1216V in inducible erythromycin-resistant Streptococcus gallolyticus subsp. pasteurianus. Antimicrob Agents Chemother (2005) 1.18
Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Am J Respir Crit Care Med (2003) 1.16
Role of RsmA in the regulation of swarming motility and virulence factor expression in Proteus mirabilis. J Med Microbiol (2003) 1.16
Antituberculosis drug resistance among retreatment tuberculosis patients in a referral center in Taipei. J Formos Med Assoc (2004) 1.16
Percutaneous computed tomography-guided coaxial core biopsy for small pulmonary lesions with ground-glass attenuation. J Thorac Oncol (2012) 1.16
Matrix-assisted laser desorption ionization-time of flight mass spectrometry can accurately differentiate between Mycobacterium masilliense (M. abscessus subspecies bolletti) and M. abscessus (sensu stricto). J Clin Microbiol (2013) 1.15
Drug resistance pattern of Mycobacterium tuberculosis in a university hospital in Taiwan, 1998-2002. J Formos Med Assoc (2004) 1.14
Pulmonary infection and colonization with nontuberculous mycobacteria, Taiwan, 2000-2012. Emerg Infect Dis (2014) 1.13
Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis (2004) 1.13
Symptoms, psychological distress, and supportive care needs in lung cancer patients. Support Care Cancer (2010) 1.12
Increased prevalence of erythromycin resistance in streptococci: substantial upsurge in erythromycin-resistant M phenotype in Streptococcus pyogenes (1979-1998) but not in Streptococcus pneumoniae (1985-1999) in Taiwan. Microb Drug Resist (2002) 1.11
Clinical and microbiological characteristics of Rhizobium radiobacter infections. Clin Infect Dis (2003) 1.11
Prognosis of tuberculous meningitis in adults in the era of modern antituberculous chemotherapy. J Microbiol Immunol Infect (2002) 1.10
The RssAB two-component signal transduction system in Serratia marcescens regulates swarming motility and cell envelope architecture in response to exogenous saturated fatty acids. J Bacteriol (2005) 1.09
Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother (2005) 1.09
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol (2014) 1.07
Pelvic abscess caused by New Delhi metallo-β-lactamase-1-producing Klebsiella oxytoca in Taiwan in a patient who underwent renal transplantation in China. Diagn Microbiol Infect Dis (2011) 1.07
Mycobacterium tuberculosis and polymorphonuclear pleural effusion: incidence and clinical pointers. Respir Med (2009) 1.07
Nutritionally variant streptococcal infections at a University Hospital in Taiwan: disease emergence and high prevalence of beta-lactam and macrolide resistance. Clin Infect Dis (2004) 1.06
In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. Microb Drug Resist (2005) 1.06
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. J Antimicrob Chemother (2002) 1.05
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol (2012) 1.05
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother (2010) 1.05